Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lantern Pharma Inc. on April 25, 2022. The registrant is a Delaware corporation with its principal executive offices in Dallas, Texas. The company is classified as an emerging growth company and its common stock trades on the Nasdaq Capital Market under the symbol "LTRN".
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report does not contain financial statements or performance metrics.
Material Changes
There are no material changes to financial performance or operations reported in this document. The filing is limited to Item 8.01 (Other Information) regarding disclosure channels.
Guidance, Outlook, and Management Commentary
Management has outlined the official channels used to disseminate material information to the public. These channels include:
- The company website (https://www.lanternpharma.com/)
- The investor relations website (https://ir.lanternpharma.com/)
- Press releases and presentations available on the investor relations site
- Social media accounts on Twitter and LinkedIn
The company encourages investors to monitor these locations for updates on technologies, clinical developments, and licensing matters.
Key Facts for Investor Verification
- Verify the company's official disclosure channels listed in Item 8.01 to ensure receipt of material information.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Note that this specific filing contains no financial data; refer to periodic reports (10-K, 10-Q) for financial metrics.